Negotiating drug prices without restricting patient access: lessons from Germany

Stat News

27 June 2019 - In the ongoing conversation about high drug prices in the United States, some loud voices argue that the solution is to allow Medicare to negotiate prices directly with manufacturers. 

The Congressional Budget Office and others say this would lead to the exclusion of some drugs from coverage, require physicians to obtain prior authorisation more often than they already do, and impose more cost sharing on patients — strategies that would keep patients from accessing medications they can benefit from.

That doesn’t have to be the case. Germany’s approach to negotiating drug prices shows that it can be done successfully without limiting access.

Read Stat News article

Michael Wonder

Posted by:

Michael Wonder